Intravitreal fasudil monotherapy in diabetic macular edema

Intravitreal fasudil monotherapy in diabetic macular edema resistant to previous anti-VEGF and corticosteroid therapy - Intravitreal fasudil monotherapy in diabetic macular edema

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031250375

Enrollment

Registered

2025-09-19

Start date

2020-09-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema diabetic macular edema

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age:20-85 years of age Diagnosis: daibetic macular edema

Exclusion criteria

Exclusion criteria: Additional exclusion criteria were history of intravitreal anti-VEGF injection, sub-Tenon triamcinolone injection, or oral carbonic anhydrase inhibitor use within the past 3 months in either eye,

Design outcomes

Primary

Measure	Time frame
visual acuity, retinal foveal thicknness	—

Secondary

Measure	Time frame
corneal endothelial cells	—

Contacts

Public ContactTetsuya Muto

Dokkyo Medical University Saitama Medical Center

ueda.castle@gmail.com+81-48-965-1111

Outcome results